-
Product Insights
Inclusion Body Myositis (IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Inclusion Body Myositis (IBM) - Drugs In Development, 2023’, provides an overview of the Inclusion Body Myositis (IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hereditary Inclusion Body Myopathy (h-IBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hereditary Inclusion Body Myopathy (h-IBM) - Drugs In Development, 2023’, provides an overview of the Hereditary Inclusion Body Myopathy (h-IBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Inclusion Body Myopathy (h-IBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulviprubart in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulviprubart in Inclusion Body Myositis (IBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulviprubart in Inclusion Body Myositis (IBM) Drug Details: Ulviprubart...
-
Sector Analysis
NewEgypt Defense Market Size, Trends, Budget Allocation, Regulations, Acquisitions, Competitive Landscape and Forecast to 2029
Egypt Defense Market Report Overview In 2024, Egypt's defense budget is worth $5.2 billion, inclusive of US military aid. The country’s defense budget will grow at a CAGR of more than 3% during 2025-2029. Egypt’s increasing military expenditure is reflected in an ongoing modernization effort to counter terrorism in the Sinai Peninsula, strained relations with Ethiopia, political turmoil following the democratic revolution, and maritime security concerns over the Suez Canal. Furthermore, the country’s strained relations with Ethiopia over the construction...
-
Product Insights
NewLikelihood of Approval Analysis for Pneumovirus Infections
Overview How likely is it that the drugs in Pneumovirus Infections will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pneumovirus Infections Overview Pneumoviridae is a family of negative-strand RNA viruses in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Inclusion Body Myositis (IBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Inclusion Body Myositis (IBM) Drug Details: Froniglutide (formerly PB-1023) is under development for the...
-
Product Insights
NewLikelihood of Approval Analysis for Idiopathic Inflammatory Myopathy (IIM)
Overview How likely is it that the drugs in Idiopathic Inflammatory Myopathy (IIM) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Inflammatory Myopathy (IIM) Overview Inflammation of muscle is known...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABC-008 in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABC-008 in Inclusion Body Myositis (IBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABC-008 in Inclusion Body Myositis (IBM) Drug Details: AB-008 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Shylicine in Diarrhea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Shylicine in Diarrhea report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Shylicine in Diarrhea Drug Details: Shylicine is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Crofelemer DR in Cholera
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crofelemer DR in Cholera report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crofelemer DR in Cholera Drug Details: Crofelemer (Fulyzaq, Mytesi) is an anti...